These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 9366446)
21. Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Shannon E; Noveck R; Sandoval F; Kamath B Immunopharmacol Immunotoxicol; 2008; 30(3):447-57. PubMed ID: 18668392 [TBL] [Abstract][Full Text] [Related]
22. In vivo IL-10 and TGF-beta production by PBMC from long-term kidney transplant recipients with excellent graft function: a possible feedback mechanism participating in immunological stability. Alberú J; Richaud-Patin Y; Vázquez-Lavista LG; de Leo C; Guzmán-Rodríguez H; Mancilla E; Correa-Rotter R; Chew-Wong A; Llorente L Clin Transplant; 2004 Apr; 18(2):174-8. PubMed ID: 15016132 [TBL] [Abstract][Full Text] [Related]
23. Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Meadows SK; Eriksson M; Barber A; Sentman CL Int Immunopharmacol; 2006 Jun; 6(6):1020-8. PubMed ID: 16644489 [TBL] [Abstract][Full Text] [Related]
24. Extracorporeal photopheresis affects interleukin (IL)-10 and IL-12 production by monocytes in patients with chronic graft-versus-host disease. Di Renzo M; Rubegni P; Pasqui AL; Pompella G; De Aloe G; Sbano P; Cuccia A; Castagnini C; Auteri A; Laghi Pasini F; Fimiani M Br J Dermatol; 2005 Jul; 153(1):59-65. PubMed ID: 16029327 [TBL] [Abstract][Full Text] [Related]
25. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. Elenkov IJ; Webster E; Papanicolaou DA; Fleisher TA; Chrousos GP; Wilder RL J Immunol; 1998 Sep; 161(5):2586-93. PubMed ID: 9725260 [TBL] [Abstract][Full Text] [Related]
26. C3 binding glycoprotein from Cuscuta europea induced different cytokine profiles from human PBMC compared to other plant and bacterial immunomodulators. Stanilova SA; Dobreva ZG; Slavov ES; Miteva LD Int Immunopharmacol; 2005 Apr; 5(4):723-34. PubMed ID: 15710341 [TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory assays to study structure-activity relationships of thalidomide. Shannon EJ; Morales MJ; Sandoval F Immunopharmacology; 1997 Jan; 35(3):203-12. PubMed ID: 9043933 [TBL] [Abstract][Full Text] [Related]
28. Theoretical basis for the activity of thalidomide. Meierhofer C; Dunzendorfer S; Wiedermann CJ BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049 [TBL] [Abstract][Full Text] [Related]
29. Thalidomide prevents formation of multinucleated giant cells (Langhans-type cells) from cultured monocytes: possible pharmaceutical applications for granulomatous disorders. Yasui K; Yashiro M; Nagaoka Y; Manki A; Wada T; Tsuge M; Kondo Y; Morishima T Int J Immunopathol Pharmacol; 2009; 22(3):707-14. PubMed ID: 19822087 [TBL] [Abstract][Full Text] [Related]
30. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha. Shannon EJ; Sandoval F; Krahenbuhl JL Immunopharmacology; 1997 Apr; 36(1):9-15. PubMed ID: 9129992 [TBL] [Abstract][Full Text] [Related]
31. Thalidomide: rationale for renewed use in immunological disorders. Schuler U; Ehninger G Drug Saf; 1995 Jun; 12(6):364-9. PubMed ID: 8527011 [TBL] [Abstract][Full Text] [Related]
32. A framework to identify gene expression profiles in a model of inflammation induced by lipopolysaccharide after treatment with thalidomide. Paiva RT; Saliba AM; Fulco TO; Sales Jde S; de Carvalho DS; Sampaio EP; Lopes UG; Sarno EN; Nobre FF BMC Res Notes; 2012 Jun; 5():292. PubMed ID: 22695124 [TBL] [Abstract][Full Text] [Related]
34. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Santos-Mendoza T; Favila-Castillo L; Oltra A; Tamaríz J; Labarrios F; Estrada-Parra S; Estrada-García L Int Arch Allergy Immunol; 1996 Sep; 111(1):13-7. PubMed ID: 8753838 [TBL] [Abstract][Full Text] [Related]
35. [Thalidomide as immunomodulatory drug: pharmacological actions and its indications]. Yasui K Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(5):229-33. PubMed ID: 21048383 [TBL] [Abstract][Full Text] [Related]
37. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Turk BE; Jiang H; Liu JO Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7552-6. PubMed ID: 8755512 [TBL] [Abstract][Full Text] [Related]
39. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. Zwingenberger K; Wnendt S J Inflamm; 1995-1996; 46(4):177-211. PubMed ID: 8878794 [TBL] [Abstract][Full Text] [Related]